On August 6, 2025, Novo Nordisk A/S reported that sales for the first half of 2025 climbed 16% to DKK 154.9 billion, with significant growth in obesity care by 56%. Despite strong sales growth, the company has lowered its full-year outlook due to increased competition and market challenges.